30 Facts About Teva Pharmaceuticals

Teva Pharmaceuticals was the largest generic drug manufacturer, when it was surpassed briefly by US-based Pfizer.

Teva Pharmaceuticals regained its market leader position once Pfizer spun off its generic drug division in a merger with Mylan, forming the new company Viatris at the end of 2020.

Teva Pharmaceuticals's facilities are located in Israel, North America, Europe, Australia, and South America.

Teva Pharmaceuticals is a member of the Pharmaceutical Research and Manufacturers of America .

Teva Pharmaceuticals's visit promoted Teva's reputation in the pharmaceutical market and created a momentum for Teva's development.

Related searches

Later on, Teva Pharmaceuticals exported its products to the US, Soviet Union, health institutes in Denmark, Czechoslovakia, Persia and Burma.

In 1954, Teva Pharmaceuticals received a Certificate Excellence in Training award from the Israeli President, Yitzhak Ben Zvi.

In 1964, Teva Pharmaceuticals partnered with Sintex, a company from Mexico, and Schering Plough.

In 1980, Teva Pharmaceuticals acquired Ikapharm, then Israel's second largest drug manufacturer.

In 1982, Teva was granted approval by the U S Food and Drug Administration for its Kfar Saba manufacturing plant.

In October 2003, Teva Pharmaceuticals announced its intentions to acquire Sicor Inc for $3.

In 2005, Teva Pharmaceuticals opened a new, state-of-the-art pharmaceutical manufacturing plant in Har Hotzvim, a technology park in Jerusalem.

Teva Pharmaceuticals entered the Japanese market in 2005, and in 2008 established a generics joint venture with Kowa.

In March 2010, Teva Pharmaceuticals acquired German-based company Ratiopharm in a deal worth almost $5 billion, significantly expanding its European coverage.

In October 2010, Teva Pharmaceuticals entered a licensing agreement with BioTime to develop and market BioTime's OpRegen for the treatment of age-related macular degeneration, an effort that in 2013 received $1.

In January 2014, Teva Pharmaceuticals acquired NuPathe, after outbidding Endo, for $144 million.

Teva Pharmaceuticals's offer for Mylan was contingent on Mylan abandoning its pursuit of Perrigo.

In October 2019, Teva Pharmaceuticals faced criticism for making a “business decision to discontinue the drug” Vincristine, essential for the treatment of most childhood cancers according to the Food and Drug Administration.

In order for the deal to gain regulatory approval, Teva sold off a number of assets, including a portfolio of five generic drugs to Sagent Pharmaceuticals for $40 million, as well as a further eight medicines to Dr Reddy's in a $350 million deal.

Teva Pharmaceuticals sold a further 15 marketed generics, as well as three others which were close to market, for $586 million to Impax Laboratories.

Also in June 2016 Teva Pharmaceuticals sold two abbreviated new drug applications to Indian pharmaceutical company Zydus Cadilla strengthen its US portfolio.

In October 2016, Teva Pharmaceuticals has sold off part of its UK and Ireland generic business to Indian pharmaceutical company Intas Pharma for 600 million pounds in cash.

Teva Pharmaceuticals agreed to sell its Plan B One-Step and its brands of emergency contraception to Foundation Consumer Healthcare for $675 million in cash.

Teva Pharmaceuticals holds patents on multiple drugs, including Copaxone, a specialty drug, now the world's best selling MS drug, and Azilect for treatment of Parkinson's disease.

In March 2015, Teva Pharmaceuticals sold four anti-cancer compounds to Ignyta Inc for $41.

Related searches

In June 2021, Teva Pharmaceuticals agreed to pay $925M to settle allegations it had engaged in price fixing in Mississippi.

In January 2022, Teva Pharmaceuticals agreed to pay $425M to settle allegations that it had concealed price fixing practices from shareholders.

In May 2019, Teva Pharmaceuticals USA agreed to pay $85 million to the U S state of Oklahoma to settle allegations that it had been overprescribing opioids, marketing them as safe, and downplaying their addictive qualities.

In February 2022, Teva Pharmaceuticals agreed to a $225 million settlement with the state of Texas to end claims that it fueled an opioid epidemic in the state by improperly marketing pain medicine.

In 2018, Teva Pharmaceuticals USA recalled tablets containing valsartan due to the detection of N-nitrosodiethylamine which is a probable human carcinogen.